Recent advances of oncolytic virus in cancer therapy
Oncolytic viruses have been taking the front stage in biological therapy for cancer recently. The first and most potent virus to be used in oncolytic virotherapy is human adenovirus. Recently, ongoing extensive research has suggested that other viruses like herpes simplex virus (HSV) and measles vir...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-10-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2020.1723363 |
| _version_ | 1797677316023779328 |
|---|---|
| author | Moumita Mondal Jingao Guo Ping He Dongming Zhou |
| author_facet | Moumita Mondal Jingao Guo Ping He Dongming Zhou |
| author_sort | Moumita Mondal |
| collection | DOAJ |
| description | Oncolytic viruses have been taking the front stage in biological therapy for cancer recently. The first and most potent virus to be used in oncolytic virotherapy is human adenovirus. Recently, ongoing extensive research has suggested that other viruses like herpes simplex virus (HSV) and measles virus can also be considered as potential candidates in cancer therapy. An HSV-based oncolytic virus, T-VEC, has completed phase Ш clinical trial and has been approved by the U.S. Food and Drug Administration (FDA) for use in biological cancer therapy. Moreover, the vaccine strain of the measles virus has shown impressive results in pre-clinical and clinical trials. Considering their therapeutic efficacy, safety, and reduced side effects, the use of such engineered viruses in biological cancer therapy has the potential to establish a milestone in cancer research. In this review, we summarize the recent clinical advances in the use of oncolytic viruses in biological therapy for cancer. Additionally, this review evaluates the potential viral candidates for their benefits and shortcomings and sheds light on the future prospects. |
| first_indexed | 2024-03-11T22:43:20Z |
| format | Article |
| id | doaj.art-f6d528c61d7d4f01b4e852d2b59d0aad |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:43:20Z |
| publishDate | 2020-10-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-f6d528c61d7d4f01b4e852d2b59d0aad2023-09-22T08:45:35ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2020-10-0116102389240210.1080/21645515.2020.17233631723363Recent advances of oncolytic virus in cancer therapyMoumita Mondal0Jingao Guo1Ping He2Dongming Zhou3Guangzhou Medical UniversityChinese Academy of SciencesGuangzhou Medical UniversityChinese Academy of SciencesOncolytic viruses have been taking the front stage in biological therapy for cancer recently. The first and most potent virus to be used in oncolytic virotherapy is human adenovirus. Recently, ongoing extensive research has suggested that other viruses like herpes simplex virus (HSV) and measles virus can also be considered as potential candidates in cancer therapy. An HSV-based oncolytic virus, T-VEC, has completed phase Ш clinical trial and has been approved by the U.S. Food and Drug Administration (FDA) for use in biological cancer therapy. Moreover, the vaccine strain of the measles virus has shown impressive results in pre-clinical and clinical trials. Considering their therapeutic efficacy, safety, and reduced side effects, the use of such engineered viruses in biological cancer therapy has the potential to establish a milestone in cancer research. In this review, we summarize the recent clinical advances in the use of oncolytic viruses in biological therapy for cancer. Additionally, this review evaluates the potential viral candidates for their benefits and shortcomings and sheds light on the future prospects.http://dx.doi.org/10.1080/21645515.2020.1723363oncolytic virusescancer therapyclinical trials |
| spellingShingle | Moumita Mondal Jingao Guo Ping He Dongming Zhou Recent advances of oncolytic virus in cancer therapy Human Vaccines & Immunotherapeutics oncolytic viruses cancer therapy clinical trials |
| title | Recent advances of oncolytic virus in cancer therapy |
| title_full | Recent advances of oncolytic virus in cancer therapy |
| title_fullStr | Recent advances of oncolytic virus in cancer therapy |
| title_full_unstemmed | Recent advances of oncolytic virus in cancer therapy |
| title_short | Recent advances of oncolytic virus in cancer therapy |
| title_sort | recent advances of oncolytic virus in cancer therapy |
| topic | oncolytic viruses cancer therapy clinical trials |
| url | http://dx.doi.org/10.1080/21645515.2020.1723363 |
| work_keys_str_mv | AT moumitamondal recentadvancesofoncolyticvirusincancertherapy AT jingaoguo recentadvancesofoncolyticvirusincancertherapy AT pinghe recentadvancesofoncolyticvirusincancertherapy AT dongmingzhou recentadvancesofoncolyticvirusincancertherapy |